Quantcast

Latest influenza A Stories

2010-12-01 12:08:00

MADISON, N.J., and CYPRESS, Calif., Dec. 1, 2010 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Focus Diagnostics Simplexa Flu A/B & RSV test on the 3M(TM) Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is intended as an...

2010-07-26 15:01:00

SAN DIEGO, July 26 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the U.S. Food and Drug Administration (FDA) has cleared for marketing Prodesse's ProFAST(TM)+ assay, making it the only FDA-cleared molecular diagnostic test to simultaneously detect and differentiate three common influenza A virus subtypes - seasonal A/H1, seasonal A/H3, and 2009 H1N1. "FDA clearance of our ProFAST+ assay is important for public health, as the test enables physicians to...

2010-06-03 16:19:07

Researchers at Mount Sinai School of Medicine have discovered a novel component of the influenza virus that may be the key to disabling the virus's ability to replicate itself and to developing a universal anti-viral treatment. The findings were published June 1 online in Proceedings of the National Academy of Sciences. The influenza A virus is encoded by eight individual single-stranded segments of RNA. Each segment must serve as the material for both making protein and new segments,...

2010-05-24 09:47:00

MADISON, N.J., and CYPRESS, Calif., May 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Simplexa(TM) Influenza A H1N1 (2009) test on the 3M(TM) Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is the first to be cleared by...

2010-04-28 06:00:00

EMERYVILLE, Calif., April 28 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco. "This pilot...

2010-03-15 05:30:00

EMERYVILLE, Calif., March 15 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session at the XII International Symposium on Respiratory...

77a3010dc4c8f006895b5e79ed45d5261
2009-12-22 11:25:00

Investigators identify host factors that help multiple influenza strains thrive and could be targeted for new antivirals Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin...

2009-11-19 07:30:00

EMERYVILLE, Calif., Nov. 19 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for...

2009-09-13 12:45:00

SAN FRANCISCO, Sept. 13 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains. The study was presented during an oral presentation at the...

2009-08-30 21:11:08

South Korea is preparing to inoculate about 9.1 million of the people at greatest risk of contracting Influenza A, the government said Sunday. Yonhap New Agency reported medical and quarantine personnel, school children, military personnel, senior citizens, pregnant women and children under age 5 will be eligible for free vaccinations. Inoculation will be available to others for $8.03 per shot. The Grand National Party said there will be earlier testing and approval of new vaccines to serve...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.